search-icon
AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Google’s $32 billion acquisition of Wiz draws antitrust attention
2
Navan to file confidentially for IPO, betting on market reopening
3
Combat-ready and camera-eyed: The X-Intra drone joins Israel’s arsenal
4
Andreessen Horowitz targets elite IDF alumni for startup accelerator
5
Intel to cut jobs at Kiryat Gat fab, says it must “position our business for the future”
More news Buzzmore

Pharmaceuricals

3 stories about Pharmaceuricals
מפעל טבע בקנדה

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
default image

United Therapeutics to Acquire Pharma Company SteadyMed in a $216 Deal

30.04.18|Amarelle Wenkert
In 2017, Israeli-founded SteadyMed won a patent war against United Therapeutics
ProfilesEngineServlet?at=39&mi=10&pt=18&dpi=1243103233&pai=cTech&dpn=4409&mt=1